Eurazeo successfully closed its latest buyout fund, Eurazeo Capital V (EC-V), securing €3bn in capital commitments and surpassing its initial target.

The fund’s strong reception highlights investor confidence in Eurazeo’s mid-large buyout strategy, which focuses on high-growth businesses with global potential.

EC-V targets mid-market companies in Europe and North America, deploying equity investments between €200m and €350m across tech-enabled business services, financial services, and healthcare and life sciences. Nearly half of the fund has already been allocated to six investments, including Spanish back-of-house software provider Mapal, French advisory firm Eres, UK and US-based specialty insurance broker BMS, global plagiocephaly treatment leader Cranial Technologies, French veterinary clinic group Sevetys, and business agility solutions provider Scaled Agile.

The fund builds on the success of Eurazeo Capital IV (EC-IV) and reinforces Eurazeo’s position as a leading mid-market investor. With a team of nearly 30 investment professionals based in Paris, London, Milan, and New York, Eurazeo secured commitments from a diverse group of global investors, including insurance companies, sovereign wealth funds, pension funds, banks, and family offices.

With EC-V, Eurazeo strengthens its capacity to support ambitious businesses, leveraging its expertise to drive long-term growth in high-potential sectors.